Innovent Biologics begins phase 1 trial of IBI315 in solid malignancies

Innovent Biologics and Beijing Hanmi Pharmaceutical, a subsidiary of Hanmi Pharmaceutical, said that the first patient has been dosed in a phase 1 clinical trial ... Read More